| My Mobile Diagnostics Llc | |
|
429 E Vermont St Ste 110 Indianapolis IN 46202-3685 | |
| (317) 559-0950 | |
| (317) 936-3028 |
| Full Name | My Mobile Diagnostics Llc |
|---|---|
| Speciality | Family Medicine |
| Location | 429 E Vermont St Ste 110, Indianapolis, Indiana |
| Authorized Official Name and Position | Steven C Martin (PARTNER) |
| Authorized Official Contact | 3176706635 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| My Mobile Diagnostics Llc 7007 Graham Rd Ste 215 Indianapolis IN 46220-4063 Ph: (317) 559-0950 | My Mobile Diagnostics Llc 429 E Vermont St Ste 110 Indianapolis IN 46202-3685 Ph: (317) 559-0950 |
| NPI Number | 1033628680 |
|---|---|
| Provider Enumeration Date | 09/27/2017 |
| Last Update Date | 04/21/2020 |
| Medicare PECOS PAC ID | 8022449669 |
|---|---|
| Medicare Enrollment ID | O20200514000795 |
News Archive
New You, the premier American consumer magazine about cosmetic surgery, will re-launch in March as the voice of the anti-aging industry in a strategic partnership with the American Academy of Anti-Aging Medicine.
INTEGRA reports on how respiratory drug discovery and development specialists - Pulmocide Ltd. (London, UK) are using a VIAFLO Assist pipetting assistant to enhance the productivity and reproducibility of their screening of novel compounds in a range of biological assays.
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study.
The American Cancer Society has issued new recommendations on when women should get mammograms and how frequently they should get them. This is in contrast to the previous guidelines which stated that women should get them at age 40.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033628680 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Joe Banks |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1154508075 PECOS PAC ID: 7113098765 Enrollment ID: I20080625000389 |
News Archive
New You, the premier American consumer magazine about cosmetic surgery, will re-launch in March as the voice of the anti-aging industry in a strategic partnership with the American Academy of Anti-Aging Medicine.
INTEGRA reports on how respiratory drug discovery and development specialists - Pulmocide Ltd. (London, UK) are using a VIAFLO Assist pipetting assistant to enhance the productivity and reproducibility of their screening of novel compounds in a range of biological assays.
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study.
The American Cancer Society has issued new recommendations on when women should get mammograms and how frequently they should get them. This is in contrast to the previous guidelines which stated that women should get them at age 40.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
› Verified 5 days ago
| Provider Name | Ryan Matthew Pickell |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1578943460 PECOS PAC ID: 3870805294 Enrollment ID: I20190904001423 |
News Archive
New You, the premier American consumer magazine about cosmetic surgery, will re-launch in March as the voice of the anti-aging industry in a strategic partnership with the American Academy of Anti-Aging Medicine.
INTEGRA reports on how respiratory drug discovery and development specialists - Pulmocide Ltd. (London, UK) are using a VIAFLO Assist pipetting assistant to enhance the productivity and reproducibility of their screening of novel compounds in a range of biological assays.
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study.
The American Cancer Society has issued new recommendations on when women should get mammograms and how frequently they should get them. This is in contrast to the previous guidelines which stated that women should get them at age 40.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
› Verified 5 days ago
News Archive
New You, the premier American consumer magazine about cosmetic surgery, will re-launch in March as the voice of the anti-aging industry in a strategic partnership with the American Academy of Anti-Aging Medicine.
INTEGRA reports on how respiratory drug discovery and development specialists - Pulmocide Ltd. (London, UK) are using a VIAFLO Assist pipetting assistant to enhance the productivity and reproducibility of their screening of novel compounds in a range of biological assays.
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study.
The American Cancer Society has issued new recommendations on when women should get mammograms and how frequently they should get them. This is in contrast to the previous guidelines which stated that women should get them at age 40.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
› Verified 5 days ago
Moazzam Habib Md Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 9240 N Meridian St, Suite 240, Indianapolis, IN 46260 Phone: 317-571-0030 Fax: 317-571-0031 | |
Shalom 56th Street-new Access Point Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 5750 W 56th St, Indianapolis, IN 46254 Phone: 317-291-7422 Fax: 317-291-4912 | |
Franciscan Health Indianapolis & Mooresville Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5230a East Stop 11 Road, Suite 250, Indianapolis, IN 46237 Phone: 317-528-8921 Fax: 317-528-6916 | |
Evernorth Care Providers - Delaware Pa Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 8888 Keystone Xing Ste 1300, Indianapolis, IN 46240 Phone: 773-292-4800 Fax: 312-564-4059 | |
Eskenazi Health Center Cottage Corner Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1434 Shelby St, Indianapolis, IN 46203 Phone: 317-655-3200 Fax: 317-655-3210 | |
Hello Wellness Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1040 E 86th St, Suite 48-a, Indianapolis, IN 46240 Phone: 317-569-1800 | |
Indiana Neurodiagnostics, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9465 Counselors Row, Ste. 200 Office 257, Indianapolis, IN 46240 Phone: 317-614-0310 Fax: 866-279-4704 |